High titers of infectious SARS-CoV-2 in COVID-19 corpses

Samples

A total of 30 specimens (11 nasopharyngeal swabs and 19 lung tissues) were collected from forensic and pathological autopsies of COVID-19 corpses in Japan between January and October 2021. Three lung tissue specimens from the 11 cases were not tested. Information on the age, sex, body mass index (kg/m²), cause of death, place of death, date of death (month), decomposition status at the time of autopsy, days from COVID-19 diagnosis to death, and PMI for each case is shown in Table 1. The date of COVID-19 diagnosis is defined here as the date of the first positive result by polymerase chain reaction (PCR) testing or as the date of death unless diagnosed before death.

Sample collection

Nasopharyngeal swabs were collected just before the autopsy. The swabs were placed in culture medium (SUGIYAMA-GEN Co., Ltd. Tokyo, Japan) and kept on ice during the autopsy and then stored at -80 °C when the autopsy was completed. An approximately 1–2 cm² pulmonary tissue sample was dissected with scissors and tweezers that were pre-wiped with 70% ethanol, kept on ice during the autopsy, and stored at -80 °C after autopsy completion. Frozen tissues were homogenized and a clarified supernatant was used for virus isolation.

RNA extraction

RNA was extracted from a 200-µL nasopharyngeal swab culture medium sample or approximately 10 mg of pulmonary tissue sample by using the Maxwell^® RSC Viral Total Nucleic Acid Purification Kit (Promega, Madison, Wisconsin, USA).

Virus quantification by real-time reverse transcription-polymerase chain reaction (RT-PCR)

Real-time RT-PCR of the N1 and N2 viral genomic regions was performed using 1 µL of the RNA preparation. The probe and primer sequences and reaction conditions were as previously published by Adachi et al. (2020) and Shirato et al. (2019). Endogenous hGAPDH-mRNA was used as an internal control, as previously described by Katano et al. (2011).

Cell culture and virus isolation

Cell culture and virus isolation were performed according to the method of Matsuyama et al. (2020). VeroE6/TMPRSS2 (JCRB1819) cells were obtained from the National Institutes of Biomedical Innovation, Health and Nutrition, Japan. Cells were maintained in Dulbecco’s modified Eagle’s medium (DMEM) containing 10% fetal calf serum (FCS) and antibiotics at 37 °C with 5% CO₂.

A 24-well plate containing a VeroE6/TMPRSS2 cell culture monolayer at a low crowding density (70–90% confluence) was prepared. After the medium was discarded, 100 μL of the undiluted sample or 10-fold dilutions of the sample were added to the cells and incubated for 1 h at 37 °C. Then, 0.5 mL of DMEM with 5% FCS and antibiotics was added and incubated at 37 °C for 1 week until a cytopathogenic effect (CPE) was observed.

Virus titration assay

Confluent Vero E6/TMPRSS2 cells in 12-well plates were infected with 100 µL of undiluted or 10-fold dilutions (10⁻¹ to 10⁻⁵) of the sample. After incubation for 1 h at 37 °C, the cells were washed once and overlaid with 1% agarose solution in DMEM with 5% FCS. The plates were incubated for 3 days and then fixed with 10% neutral buffered formalin. After removal of the agar, the plaques were counted.

Biosafety statement

All experiments with SARS-CoV-2 viruses were performed in the University of Tokyo’s enhanced biosafety level 3 containment laboratories, which are approved for such use by the Ministry of Agriculture, Forestry, and Fisheries, Japan.

Viral genomic copy number and infectious virus titers

Infectious virus was detected in 6 (Cases 2, 3, 4, 6, 10, and 11) of 11 cases and 13 (four nasopharyngeal swabs and nine lung tissue specimens) of 30 specimens (Table 2). Figure 1 shows the relationship between viral genomic copy number on the autopsy date, time (days) from the COVID-19 diagnosis to the autopsy date, and the presence or absence of infectious virus. Infectious virus titers ranged from 6.00 E + 01 plaque-forming units (PFU)/mL to 6.00 E + 03 PFU/mL in nasopharynx swabs and from 3.89 E + 02 PFU/g to 2.09 E + 06 PFU/g in lung tissues. The viral genomic copy number for the specimens ranged from the third power of 10 to the seventh power of 10, except in Case 1. Of the 13 specimens containing infectious virus, the lowest viral genomic copy number (3,840 copies/µL) was found in the left lung tissue of Case 11, which had an infectious titer of 1.27E + 04 PFU/g. Of the 17 specimens containing non-infectious virus, the highest viral genomic copy number (7.23E + 06 copies/µL) was found in the left lung tissue of Case 5.

• Download figure
• Open in new tab

Figure 1.

Bubble chart showing the relationship between viral genomic copy number on the autopsy date, days from the COVID-19 diagnosis to the autopsy date, and the presence or absence of infectious virus.

¶The numbers around the bubble indicate the infectious titer and the size of the bubble represents the magnitude of the infectious titer.

Of the two hospitalized cases (Cases 2 and 5), infectious virus was found in Case 2, in which the patient had been hospitalized for cirrhosis, contracted COVID-19 in the hospital, and died of severe pneumonia. In Case 5, the patient was hospitalized for 8 days after COVID-19 diagnosis, died despite clinical treatment, and was autopsied 4 days after death. In this case, the viral genomic copy number was in the million-copy range for the nasopharyngeal swab and the left and right lungs, but none of the specimens contained infectious virus.

No infectious virus was detected in Case 1, for which the viral genomic copy number was low, but this body was found in a pond 4 days after discharge when COVID-19 was already cured; the cause of death was drowning.

Of the eight non-hospitalized patients, virus was isolated in five cases (Cases 3, 4, 6, 10, and 11) and no infectious virus was detected in the other three cases (Cases 7, 8, and 9).

In two cases (Cases 3 and 4), the patients had been recuperating in hotel rooms without clinical treatment and were found to contain infectious virus. Among the three cases (Cases 6, 7, and 8) of patients that were recovering at home, the corpse in Case 6 contained infectious virus whereas the other two cases did not. The patient in Case 6 had a body mass index of 38.6 (i.e., was obese) and died at home 2 days after COVID-19 diagnosis. In contrast, the patient in Case 7 died 9 days after diagnosis and was found 3 days after death, and the patient in Case 8 died 3 days after diagnosis and was found 4 days after death in a highly decomposed state.

In the three cases (Cases 9, 10, and 11) of persons found dead at home, the corpses in Cases 10 and 11 were found to contain infectious virus; however, both were in poor health before death and were found to be positive by postmortem PCR testing. The corpse in Case 9 was in a highly decomposed state and infectious virus was not found.

State of the corpses

Infectious virus was detected in three (Cases 2, 4 and 6) of the four cases (Cases 2, 4, 6, and 8) for which 4 days or less had elapsed from antemortem diagnosis to death.

The two cases (Cases 10 and 11) of three cases (Cases 9, 10 and 11) in which infection was detected by postmortem PCR testing were stored in a refrigerator the day after death; the left and right lungs of both corpses showed high infectious titers. These two cases were not decomposed.

In the two cases (Cases 8 and 9) for which infectious virus was not detected, the corpses had been left at room temperature before discovery and were highly decomposed.

Virus was isolated from six of the seven cases in which the time from death to discovery was within 1 day. In these six cases, the period of refrigeration ranged from 2 to 12 days and the PMI ranged from 3 to 13 days. Case 5 was the only case from which the virus was not isolated; the patient in this case died 8 days after starting COVID-19 treatment.